Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses

Cancer Research

Volumn 67, Issue 3, 2007, Pages 1299-1307

  Bilsland, Alan E ^a   Merron, Andrew ^b   Vassaux, Georges ^b   Keith, W Nicol ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CONDITIONALLY REPLICATING ADENOVIRUS; E1A PROTEIN; LUCIFERASE; ONCOLYTIC ADENOVIRUS; ONCOLYTIC CYTOMEGALOVIRUS; RNA DIRECTED DNA POLYMERASE; TELOMERASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA REPLICATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; BASE SEQUENCE; CELL LINE, TUMOR; HUMANS; MOLECULAR SEQUENCE DATA; ONCOLYTIC VIRUSES; PROMOTER REGIONS (GENETICS); RNA; TELOMERASE; VIRUS REPLICATION;

EID: 33847074257     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3000     Document Type: Article

References (47)

1. Autexier C, Pruzan R, Funk WD, Greider CW. Reconstitution of human telomerase activity and identification of a minimal functional region of the human telomerase RNA. EMBO J 1996;15:5928-35.
2. Bachand F, Autexier C. Functional regions of human telomerase reverse transcriptase and human telomerase RNA required for telomerase activity and RNA-protein interactions. Mol Cell Biol 2001;21:1888-97.
3. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-91.
4. White LK, Wright WE, Shay JW. Telomerase inhibitors. Trends Biotechnol 2001;19:114-20.
5. Nicol Keith W, Jeffry Evans TR, Glasspool RM. Telomerase and cancer: time to move from a promising target to a clinical reality. J Pathol 2001;195:404-14.
6. Lavelle F, Riou JF, Laoui A, Mailliet P. Telomerase: a therapeutic target for the third millennium? Crit Rev Oncol Hematol 2000;34:111-26.
7. Keith WN, Bilsland A, Evans TR, Glasspool RM. Telomerase-directed molecular therapeutics. Expert Rev Mol Med 2002;2002:1-25.
8. Keith WN, Sarvesvaran J, Downey M. Analysis of telomerase RNA gene expression by in situ hybridization. Methods Mol Biol 2002;191:65-81.
9. Downey MG, Going JJ, Stuart RC, Keith WN. Expression of telomerase RNA in oesophageal and oral cancer. J Oral Pathol Med 2001;30:577-81.
10. Wisman GB, De Jong S, Meersma GJ, et al. Telomerase in (pre)neoplastic cervical disease. Hum Pathol 2000;31:1304-12.
11. Sarvesvaran J, Going JJ, Milroy R, Kaye SB, Keith WN. Is small cell lung cancer the perfect target for anti-telomerase treatment? Carcinogenesis 1999;20:1649-51.
12. Soder AI, Going JJ, Kaye SB, Keith WN. Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization. Oncogene 1998;16:979-83.
13. Soder AI, Hoare SF, Muir S, Going JJ, Parkinson EK, Keith WN. Amplification, increased dosage, and in situ expression of the telomerase RNA gene in human cancer. Oncogene 1997;14:1013-21.
14. Bilsland AE, Fletcher-Monaghan A, Keith WN. Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy. Neoplasia 2005;7:1020-9.
15. Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 2003;22:370-80.
16. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Keith WN, Vassaux G. Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res 2004;64:4906-11.
17. Plumb JA, Bilsland A, Kakani R, et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 2001;20:7797-803.
18. Abdul-Ghani R, Ohana P, Matouk I, et al. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther 2000;2:539-44.
19. Dufes C, Keith WN, Bilsland A, Proutski I, Uchegbu IF, Schatzlein AG. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res 2005;65:8079-84.
20. Boyd M, Mairs RJ, Keith WN, et al. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. J Gene Med 2004;6:937-47.
21. Koga S, Hirohata S, Kondo Y, et al. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 2000;11:1397-406.
22. Komata T, Koga S, Hirohata S, et al. A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter. Int J Oncol 2001;19:1015-20.
23. Komata T, Kondo Y, Kanzawa T, et al. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 2001;61:5796-802.
24. Liu J, Zou WG, Lang MF, et al. Cancer-specific killing by the CD suicide gene using the human telomerase reverse transcriptase promoter. Int J Oncol 2002;21:661-6.
25. Majumdar AS, Hughes DE, Lichtsteiner SP, Wang Z, Lebkowski JS, Vasserot AP. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther 2001;8:568-78.
26. Keith WN, Bilsland A, Hardie M, Evans TR. Drug insight: cancer cell immortality-telomerase as a target for novel cancer gene therapies. Nat Clin Pract Oncol 2004;1:88-96.
27. Gu J, Zhang L, Huang X, et al. A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo. Oncogene 2002;21:4757-64.
28. Grace MJ, Xie L, Musco ML, et al. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies. Am J Pathol 1999;155:1869-78.
29. Grill J, Lamfers ML, van Beusechem VW, et al. The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Mol Ther 2002;6:609-14.
30. Huebner RJ, Rowe WP, Schatten WE, Smith RR, Thomas LB. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956;9:1211-8.
31. Frisch SM, Mymryk JS. Adenovirus-5 E1A: paradox and paradigm. Nat Rev Mol Cell Biol 2002;3:441-52.
32. Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 2005;12:141-61.
33. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther 2002;13:1737-50.
34. Kawashima T, Kagawa S, Kobayashi N, et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004;10:285-92.
35. Kim E, Kim JH, Shin HY, et al. Ad-mTERT-Δ19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 2003;14:1415-28.
36. Wirth T, Kuhnel F, Fleischmann-Mundt B, et al. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Cancer Res 2005;65:7393-402.
37. Zou W, Luo C, Zhang Z, et al. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene 2004;23:457-64.
38. Irving J, Wang Z, Powell S, et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther 2004;11:174-85.
39. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998;95:2509-14.
40. Bilsland AE, Stevenson K, Atkinson S, Kolch W, Keith WN. Transcriptional repression of telomerase RNA gene expression by c-Jun-NH2-kinase and Sp1/Sp3. Cancer Res 2006;66:1363-70.
41. Madhusudan S, Tamir A, Bates N, et al. A multicenter phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res 2004;10:2986-96.
42. Richter JD, Young P, Jones NC, Krippl B, Rosenberg M, Ferguson B. A first exon-encoded domain of E1A sufficient for posttranslational modification, nuclear-localization, and induction of adenovirus E3 promoter expression in Xenopus oocytes. Proc Natl Acad Sci U S A 1985;82:8434-8.
43. Smith CL, Debouck C, Rosenberg M, Culp JS. Phosphorylation of serine residue 89 of human adenovirus E1A proteins is responsible for their characteristic electrophoretic mobility shifts, and its mutation affects biological function. J Virol 1989;63:1569-77.
44. Bortolanza S, Qian C, Kramer MG, et al. An oncolytic adenovirus controlled by a modified telomerase promoter is attenuated in telomerase-negative cells, but shows reduced activity in cancer cells. J Mol Med 2005;83:736-47.
45. Glasspool RM, Burns S, Hoare SF, Svensson C, Keith NW. The hTERT and hTERC telomerase gene promoters are activated by the second exon of the adenoviral protein, E1A, identifying the transcriptional corepressor CtBP as a potential repressor of both genes. Neoplasia 2005;7:614-22.
46. Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WS. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 1996;70:2296-306.
47. Spindler KR, Berk AJ. Rapid intracellular turnover of adenovirus 5 early region 1A proteins. J Virol 1984;52:706-10.